[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

MCRT Webcast: Three Newly Approved Myeloma Treatments - July 11, 2020

MCRT Webcast: Three Newly Approved Myeloma Treatments - July 11, 2020 image

MCRT Webcast: Three Newly Approved Myeloma Treatments - July 11, 2020

Roundtable
event Jul 11, 2020 / 09:00AM - 03:00PM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Three novel myeloma therapies— selinexor (XPOVIO ®), isatuximab (Sarclisa ®), and daratumumb subcutaneous (DARZALEX Faspro ®)— were discussed by three top experts in the Myeloma Crowd Round Table Interactive Webcast held on July 11, 2020.

 

Thanks to our Round Table sponsors

  

 

 

Virtual Round Table, July 11, 2020

Three Newly Approved Myeloma Treatments

expand_more

Schedule & Agenda

Event panelist  Dr. Joshua Richter, Dr. Paul Richardson, Dr. Jonathan Kaufman
09:00 AM
Round Table
Dr. Joshua Richter, Dr. Paul Richardson, Dr. Jonathan Kaufman

Speakers & Moderators

The panelist Joshua Richter, MD
Joshua Richter, MD

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.

Read Bio
The panelist Paul Richardson, MD
Paul Richardson, MD

Paul Richardson, MD, is the RJ Corman Professor of Medicine at the Harvard Medical School, Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, of the Dana-Farber Cancer Institute (DFCI) in Boston. Dr. Richardson received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, UK. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, USA. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute before coming on staff at DFCI in 1994. Dr. Richardson currently holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He is the prior Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; The Tisch Outstanding Achievement Award for Clinical Research; and the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012, the Ernest Beutler Prize at ASH 2015, and the Robert A Kyle Lifetime Achievement Award in 2017.

Read Bio
The panelist Jonathan Kaufman, MD
Jonathan Kaufman, MD

Jonathan Kaufman, MD, is Associate Professor and Associate Vice-Chair for Quality and Safety of the Department of Hematology and Medical Oncology at the Emory University School of Medicine. Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant. His research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders. Additionally, Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with American Society of Clinical Oncology and American Society of Hematology. Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Takeda Oncology logo
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.